Hospital Stocks: Regulatory Risk Comes Into Focus

, Max Healthcare, Fortis Healthcare and other private hospital stocks came under selling pressure after the Supreme Court raised concerns over high mark-ups on medicines sold through corporate hospitals. The Court highlighted a case where a cancer drug with a price to retailer of around ₹2,700 carried an MRP of ₹27,000 and questioned whether a uniform 16% margin should apply to medicines and medical devices. The Court also questioned the practice of requiring patients to purchase medicines through in-house hospital pharmacies. The matter has been referred to the Centre for consideration, with the next hearing scheduled for October 12, 2026. Importantly, the 16% margin is currently an observation under consideration and is not a binding pricing regulation. For listed hospitals, the key concern is the potential impact on pharmacy-related revenue and margins if tighter pricing controls or restrictions on in-house pharmacy sales are eventually introduced. The actual financial impact will depend on the final regulatory framework and the extent of exposure of individual hospital chains. Investors should therefore monitor the government's response, the October 12 hearing and subsequent company disclosures.